Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OKYO Pharma Limited
OKYO | US
1.51
USD-0.07
-4.43%
OKYO | US
About OKYO Pharma Limited
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2023
As of date
10/04/2026
Close
1.51
Open
1.64
High
1.67
Low
1.50
OKYO Pharma Limited a preclinical biopharmaceutical company engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201 a bovine adrenal medulla lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London the United Kingdom.
View LessOKYO | US
Risk
49.8
Sharpe
0.39
Luna's Score
36/100
Recommendation
Sell
Luna says (OKYO | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
60.8%1 month
49.8%3 months
91.2%6 months
92.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
14.11
Debt to equity
-1.08
Debt to assets
0.43
Ent. to EBITDA
-4.29
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-15.75M
MarketCap
51.09M
MarketCap(USD)
51.09M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-2.97K
Short ratio
5.77
Short perc.
0.86
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.28
Range1M
0.31
Range3M
1.76
Volumes: Market Activity
Rel. volume
1.99
Price X volume
267.35K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.29 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 14.11 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 91.25 | - | Riskier |
| Debt to Equity | -1.08 | -1.23 | Cheaper |
| Debt to Assets | 0.43 | 0.25 | Expensive |
| Market Cap | 51.09M | - | Emerging |
